Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery

Drug Discovery Today

Volumn 14, Issue 5-6, 2009, Pages 261-270

  Hohman, Moses ^a   Gregory, Kellan ^a   Chibale, Kelly ^b   Smith, Peter J ^b   Ekins, Sean ^c,d,e   Bunin, Barry ^a  

^a Collaborative Drug Discovery Inc ^*  (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Collaborations in Chemistry ^*  (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIMALARIAL AGENT; CHLOROQUINE; CHLORPROMAZINE; CRA 10892; CRA 17345; CRA 17408; CRA 17545; CRA 24356; CRA 24397; CRA 24569; CYPROHEPTADINE; DESIPRAMINE; DIHYDROERGOTAMINE MESILATE; PENFLURIDOL; PIMOZIDE; SERTRALINE; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

BIOINFORMATICS; DATA BASE; DRUG INFORMATION; DRUG RESEARCH; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; INTERNET; NONHUMAN; ONLINE SYSTEM; PATENT; REVIEW; SOCIAL NETWORK;

ANTIMALARIALS; COOPERATIVE BEHAVIOR; DATABASES, FACTUAL; DRUG DISCOVERY; HUMANS; INFORMATION SERVICES; INTELLECTUAL PROPERTY; INTERNET; SOCIAL SUPPORT; SOFTWARE; SYSTEMS BIOLOGY;

EID: 61849137243     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.11.015     Document Type: Review

References (41)

1. Carpy A.J., and Marchand-Geneste N. Structural e-bioinformatics and drug design. SAR QSAR Environ. Res. 17 (2006) 1-10
2. Ertl P., and Jelfs S. Designing drugs on the internet? Free web tools and services supporting medicinal chemistry. Curr. Top Med. Chem. 7 (2007) 1491-1501
3. Munos B. Can open-source R&D reinvigorate drug research?. Nat. Rev. Drug Discov. 5 (2006) 723-729
4. Williams A.J. Internet-based tools for communication and collaboration in chemistry. Drug Discov. Today 13 (2008) 502-506
5. Williams A.J. A perspective of publicly accessible/open-access chemistry databases. Drug Discov. Today 13 (2008) 495-501
6. Ekins S., et al. Molecular characterization of CYP2B6 substrates. Curr. Drug Metab. 9 (2008) 363-373
7. Ekins S., et al. Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol. Pharmacol. 74 (2008) 662-672
8. Nwaka S., and Ridley R.G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug Discov. 2 (2003) 919-928
9. Ekins S., et al. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br. J. Pharmacol. 152 (2007) 9-20
10. Newman M.E.J. Random graphs as models of networks. In: Bornholdt S., and Schuster H.G. (Eds). Handbook of Graphs and Networks (2003), Wiley-VCH 35-68
11. Barabasi A.-L., and Oltvai Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 5 (2004) 101-113
12. Lee S., and Bozeman B. The impact of research collaboration on scientific productivity. Soc. Stud. Sci. 35 (2005) 673-702
13. Katsouyanni K. Collaborative research: accomplishments & potential. Environ. Health 7 (2008) 3
14. Guimera R., et al. Team assembly mechanisms determine collaboration network structure and team performance. Science 308 (2005) 697-702
15. In: Bunin B.A., et al. (Ed). Cheminformatics Theory, Practice, and Products (2007), Springer-Verlag
16. Radish J. More medicines for neglected and emerging infectious diseases. Bull. World Health Organ. 85 (2007) 569-648
17. Grace, C. (2006) Developing new technologies to address neglected diseases: the role of product development partnerships and advanced market commitments, Department for International Development (DFID) Health Research Center Report
18. Wechsler, J. (2007) Manufacturers Tackle Neglected Diseases in http://biopharminternational.findpharma.com/biopharm/Article/Manufacture rs-Tackle-Neglected-Diseases/ArticleStandard/Article/detail/439419
19. Chouteau F., et al. Exploiting a basic chemosensitizing pharmacophore hypothesis. Part 1: synthesis and biological evaluation of novel arylbromide and bicyclic chemosensitizers against drug-resistant malaria parasites. Bioorg. Med. Chem. Lett. 15 (2005) 3024-3028
20. Chiyanzu I., et al. Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. Bioorg. Med. Chem. 13 (2005) 3249-3261
21. Weisman J.L., et al. Searching for new antimalarial therapeutics amongst known drugs. Chem. Biol. Drug Des. 67 (2006) 409-416
22. Gold B., et al. Identification of a copper-binding metallothionein in pathogenic mycobacteria. Nat. Chem. Biol. 4 (2008) 609-616
23. Tran C.V., and Saier Jr. M.H. The principal chloroquine resistance protein of Plasmodium falciparum is a member of the drug/metabolite transporter superfamily. Microbiology 150 Pt 1 (2004) 1-3
24. Warhurst D.C. Polymorphism in the Plasmodium falciparum chloroquine-resistance transporter protein links verapamil enhancement of chloroquine sensitivity with the clinical efficacy of amodiaquine. Malar. J. 2 (2003) 31
25. O'Connor K.A., and Roth B.L. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug Discov. 4 (2005) 1005-1014
26. Chong C.R., and Sullivan Jr. D.J. New uses for old drugs. Nature 448 (2007) 645-646
27. Chong C.R., et al. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat. Chem. Biol. 2 (2006) 415-416
28. Sannella A.R., et al. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett. 582 (2008) 844-847
29. In: Wiselogle F.Y. (Ed). A Survey of Antimalarial Drugs 1941-1945 (1946), J.W. Edwards
30. de Cerqueira Lima P., et al. Combinatorial QSAR modeling of P-glycoprotein substrates. J. Chem. Inf. Model 46 (2006) 1245-1254
31. Kovatcheva A., et al. QSAR modeling of datasets with enantioselective compounds using chirality sensitive molecular descriptors. SAR QSAR Environ. Res. 16 (2005) 93-102
32. Nwaka S., and Hudson A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5 (2006) 941-955
33. Clark J.E., et al. Novel trends in orphan market drug discovery: amyotrophic lateral sclerosis as a case study. Front. Biosci. 7 (2002) c83-c96
34. White H.S., et al. The National Institutes of Health Anticonvulsant Drug Development program: screening for efficacy. Adv. Neurol. 76 (1998) 29-39
35. Escolar D.M., et al. Collaborative translational research leading to multicenter clinical trials in Duchenne muscular dystrophy: the Cooperative International Neuromuscular Research Group (CINRG). Neuromuscul. Disord. 12 Suppl. 1 (2002) S147-154
36. Kanehisa M.A., et al. The KEGG databases at GenomeNet. Nucleic Acids Res. 30 (2002) 42-46
37. Strachan R.T., et al. Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discov. Today 11 (2006) 708-716
38. Roth B.L., et al. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol. Ther. 102 (2004) 99-110
39. Ekins S., et al. Pathway mapping tools for analysis of high content data. Methods Mol. Biol. 356 (2007) 319-350
40. Pico A.R., et al. WikiPathways: pathway editing for the people. PLoS Biol. 6 (2008) e184
41. Wright J., and Wagner A. The systems biology research tool: evolvable open-source software. BMC Syst. Biol. 2 (2008) 55